Cooley: Abivax Announces $235.8M Initial Public Offering
October 30, 2023
October 30, 2023
NEW YORK, Oct. 30 -- Cooley, a law firm, issued the following news release:
Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Abivax offered a total of 20 . . .
Cooley advised Abivax, a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, on its $235.8 million initial public offering.
Partners Div Gupta, Marc Recht, Ryan Sansom and Denny Won led the Cooley team.
Abivax offered a total of 20 . . .